# Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

> **NCT05281471** · PHASE3 · RECRUITING · sponsor: **Genelux Corporation** · enrollment: 186 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-grade Serous Ovarian Cancer
- Endometrioid Ovarian Cancer
- Ovarian Clear Cell Carcinoma

## Interventions

- **BIOLOGICAL:** olvimulogene nanivacirepvec
- **DRUG:** Platinum chemotherapy: carboplatin (preferred) or cisplatin
- **DRUG:** Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- **DRUG:** Bevacizumab (or biosimilar)

## Key facts

- **NCT ID:** NCT05281471
- **Lead sponsor:** Genelux Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2026-06
- **Final completion:** 2026-10
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281471, "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05281471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*